SecurityGGP / GGP, Inc. (370023103)
IndustryReal Estate Investment Trusts
Institutional Owners17
Institutional Shares50,656,065 - 5.26%
Common Shares Outstanding962,460,117 shares (as of 2018-06-30)
Institutional Value$ 1,264,436,000 USD
Related BPR / Brookfield Property REIT Inc. Class A
GGP / General Growth Properties, Inc.
GGP.PRA / General Growth Properties, Inc.

Institutional Stock Ownership and Shareholders

GGP, Inc. (NYSE:GGP) has 17 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 50,656,065 shares. Largest shareholders include BlackRock Institutional Trust Company, N.A., BlackRock Fund Advisors, BlackRock Group LTD, BlackRock Investment Management, LLC, BlackRock Advisors LLC, BlackRock Japan Co. Ltd, Group One Trading, L.p., Gulf International Bank (UK) Ltd, Group One Trading, L.p., and Mizuho Asset Management Co.,Ltd..
GGP, Inc. (NYSE:GGP) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.

File DateFormInvestor Opt Prev
Prev Value
Current Value
2018-07-30 13F-HR EII CAPITAL MANAGEMENT, INC. 43,600 43,600 0.00 1,079 1,042 -3.43
2018-08-13 13F-HR GROUP ONE TRADING, L.P. Put 320,600 413,100 28.85 6,559 8,440 28.68
2016-11-14 13F-HR MASON STREET ADVISORS, LLC 78,993 2,180
2017-02-10 13F-HR BlackRock Fund Advisors 18,798,914 17,469,089 -7.07 518,850 436,378 -15.90
2017-02-10 13F-HR BlackRock Investment Management, LLC 1,369,323 1,422,939 3.92 37,793 35,545 -5.95
2018-08-13 13F-HR GROUP ONE TRADING, L.P. Call 302,100 213,200 -29.43 6,181 4,356 -29.53
2017-05-15 13F-HR R&F Capital Advisors LP 15,838 0 -100.00 396 0
2017-01-13 13F-HR MetLife Securities, Inc 171 1,576 821.64 5 39 680.00
2017-02-10 13F-HR BlackRock Advisors LLC 577,863 926,423 60.32 15,949 23,142 45.10
2017-05-01 13F-HR Spot Trading L.L.C Put 40,000 0 -100.00 999 0
2017-02-10 13F-HR BlackRock Group LTD 7,477,528 7,383,179 -1.26 206,380 184,432 -10.63
2017-05-16 13F-HR JANUS CAPITAL MANAGEMENT LLC 293,087 0 -100.00 7,321 0 -100.00
2017-01-27 13F-HR Forum Securities Ltd 2,741 3,141 14.59 76 78 2.63
2017-02-10 13F-HR BlackRock Japan Co. Ltd 812,692 862,061 6.07 22,430 21,534 -3.99
2017-02-10 13F-HR BlackRock Institutional Trust Company, N.A. 21,169,026 21,961,063 3.74 584,265 548,587 -6.11
2017-05-12 13F-HR/A DELTA LLOYD NV 512,783 0 -100.00 12,809 0 -100.00
2018-07-05 13F-HR Gulf International Bank (UK) Ltd 191,334 225,214 17.71 3,914 4,601 17.55
2016-11-14 13F-HR Mizuho Asset Management Co.,Ltd. 164,200 4,532
2018-08-10 13F-HR BARR E S & CO 25,225 23,225 -7.93 516 474 -8.14
2018-08-21 13F-HR SRS Capital Advisors, Inc. 523 512 -2.10 10 10 0.00
2018-08-13 13F-HR CIBC WORLD MARKETS CORP 81,880 89,350 9.12 1,675 1,825 8.96
2017-05-01 13F-HR Spot Trading L.L.C 10,501 0 -100.00 262 0
2018-09-19 13F-HR ROYAL LONDON ASSET MANAGEMENT LTD 177,980 0 -100.00 5,310 0 -100.00

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

Related News Stories

Giggles N' Hugs Inc. (GIGL) CEO Joey Parsi on Q2 2018 Results - Earnings Call Transcript

2018-09-17 seekingalpha
Giggles N’ Hugs Inc. (OTCQB:GIGL) Q2 2018 Results Earnings Conference Call September 17, 2018 2:00 PM ET (1-0)

Simon Property Group: The Top SWAN In Retail Real Estate

2018-09-17 seekingalpha
I initially favored SKT over SPG, but have since learned that - especially in retail - quality matters. (4-0)

Strong Buy 6.16% Yield Won't Be On Sale Forever

2018-09-13 seekingalpha
They are very firmly within the investment grade credit rating and have significant excess cash flow even after paying the common dividend. (1-0)

Redmond Overlake Plaza: One Reason Why Valuing Seritage Growth Is Difficult

2018-09-13 seekingalpha
The balance sheet numbers based on how the property sits now don’t help us understand the future economics. (9-0)

Fat-Pitch Catalyzed. What's Next For Brookfield Property Partners?

2018-09-05 seekingalpha
We now analyze the combined company and explain why it is a good but risky investment. (2-0)

How To Retire In 2018 In A Bull Market Without Going To Cash

2018-08-29 seekingalpha
Retiring in the market today can be scary, but we will go over how to avoid the landmines. (23-0)

Bruce Berkowitz, From 'The Best Manager Of The 2000s' To Underperforming In Recent Years: The Bets Of An Unconventional Fund Manager

2018-08-28 seekingalpha
Bruce Berkowitz manages Fairholme Fund (FAIRX), a non-diversified mutual fund focused on the US market that has beat the S&P 500 since its inception in 1999. (29-2)

Here’s How to Profit From the Breakout in Arista Networks

2018-08-27 investorplace
Many try, but most fail when trying to transition from the new kid on the block to the big leagues of investing. One stock doing just that, however, is Arista Networks (NYSE:ANET). But if you’re bullish on ANET stock, going long a slightly out-of-the-money bull call spread still looks good. Let me explain. (6-0)

Washington Prime Group Offers Favorable Risk-Reward

2018-08-27 seekingalpha
Washington Prime Group is not for the faint of heart and will likely encounter significant volatility in the months and years to come. (14-1)

Why I Changed My Mind About Brookfield Property Partners

2018-08-24 seekingalpha
I was initially - and remain - concerned by BPY's high level of leverage, and therefore preferred to gain exposure to units via BAM shares. (2-1)

CUSIP: 370023103